Increasing Access to HIV/AIDS Treatment in Developing Countries

Partnership to increase access to Roche’s diagnostic tests and medicines for diagnosing, treating and monitoring patients with HIV/AIDS through no/reduced-profit pricing and enabling manufacturing of antiretroviral therapies by other companies through technology transfer .

Access to HIV/AIDS Diagnostics and Anti-retroviral Treatments

"Roche has committed to transparent pricing and patent policies to address barriers to its HIV diagnostics tests and second-line HIV protease inhibitor medicine in low- and middle-income countries.

Roche supplies its protease inhibitor Invirase (saquinavir) at non-profit prices for people living in these countries, including all of sub Saharan Africa (SSA). This covers 63 countries, which are home to 64% of all people living with HIV/AIDS.

These are the lowest prices at which the medicines can viably be sold in the long term and do not reflect research or development costs, marketing costs, distribution costs or company overheads. Roche also supplies Invirase at significantly reduced prices in middle-income and emerging countries where HIV/AIDS is a growing problem.

Since 2007, the company has provided Valcyte (valganciclovir), an oral medication for treating AIDS-related cytomegalovirus retinitis (CMVR), at reduced prices for AIDS treatment programmes led by non-governmental organisations in low- and middle-income countries and in sub-Saharan Africa. In 2013, through a purchase agreement with the Medicines Patent Pool, Roche further reduced the price for Valcyte for use in HIV patients, making it 90% cheaper for 138 developing countries, including a number of upper middle-income countries such as India and China.

Through the AmpliCare program, Roche supplies diagnostic HIV tests at the lowest possible price in SSA countries and several countries in South America and Asia.

Roche does not file for new patents or enforce existing patents on Roche medicines in Least Developed Countries (LDCs) or low income countries. In addition, Roche does not file or enforce patents for antiretroviral HIV medicines in sub-Saharan Africa. Not applying patents in these regions enables generic versions of Roche medicines to be produced and distributed in these countries. In addition, through programs like Roche’s Technology Transfer Initiative (completed in 2010), local manufacturers now have the necessary skills to produce generic versions of the HIV medications."


  • Roche International

    Works & Construction, Development Consulting
    Canada | Staff size: 501-1000

    Drawing on the knowledge and professionalism of its 1,500 employees, Roche Ltd, Consulting Group is now a major Canadian engineering-construction firm that was founded in La Malbaie, Quebec, in...

  • Aspen Pharmacare

    Goods Supplier
    South Africa | Staff size: 5001-10,000

    Aspen Pharmacare Holdings Limited is a multinational South African holding company for pharmaceutical concerns. The Group is committed to sustaining life and promoting healthcare through...

  • Adcock Ingram

    Goods Supplier
    South Africa | Staff size: 26-50

    Adcock Ingram is a leading South African pharmaceutical manufacturer, listed on the Johannesburg Stock Exchange.

    The Company manufactures, markets and distributes a wide range of...

  • Cosmos Limited

    Goods Supplier
    Kenya | Staff size: 26-50

    The importance of medicines can only be realized if they are readily available when required. With that in mind Cosmos started in 1978 with the sole aim of manufacturing quality medicines at an...

  • Shelys Pharmaceuticals

    Goods Supplier
    Tanzania | Staff size: 101-250

    Shelys Pharmaceuticals is a renowned pharmaceutical company of Sub Saharan Africa. Shelys has humble origins starting as a diminutive family business in 1956 and has, over the years, established...

  • Medicines Patent Pool (MPP)

    Implementing NGO, Goods Supplier
    Staff size: 26-50

    The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to HIV, viral hepatitis C and tuberculosis treatments in low- and middle-income...

More Resources

Key Information

LocationEast Asia and Pacific, West Africa, Central Africa, Central Asia, Eastern Africa, Latin America and Caribbean, South Asia, Southern Africa
  • Start Date 2002